This summarizes pretty well the fate of the hydroxychloroquine azitromycin treatment, while there are numerous research programs now being started, with double blinded protocols.
Researchers may rejoice, with big contracts and certainly more and more contracts to come, even when their research protocols are flawed.
Many volunteer patients in those trials will be brought to their death by receiving placebos instead of the therapy now proven to be effective.
Meanwhile, most of the population will not have access to effective treatment, even if such treatment now exists and is being delivered successfully in places such as Marseille.
Q: You don’t send him the life buoy?
A: I don’t know. I don’t think it is homologated.